Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation.
Newly diagnosed aplastic anemia is a serious condition, with more than 75% (higher in young patients) becoming long-term survivors if diagnosed and treated appropriately. First-line treatment approaches include immunosuppressive treatment using the combination of antithymocyte globulin and cyclosporine A for patients without a sibling donor and HLA identical sibling transplant for patients younger than age 40 with a donor. Best transplant strategies have been defined and include conditioning with cyclophosphamide and antithymocyte globulin, marrow as a stem cell source, and graft-versus-host diease prophylaxis using cyclosporine A and methotrexate. It is against these standard treatment approaches that any therapeutic progress has to be measured.
Hematology Division, Geneva University Hospital, Geneva, Switzerland. Jakob.passweg@hcuge.ch
Jakob R
JR
Passweg
Judith C W
JC
Marsh
D000741:Anemia, Aplastic / Q000628:therapy*; D016026:Bone Marrow Transplantation; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D035781:Siblings; D014019:Tissue Donors
D006680:HLA Antigens